FDA Grants Fast Track Designation to BioXcel Therapeutics' Novel Prostate Cancer Therapy

BXCL701 is an oral innate immune activator being investigated in combination with Keytruda (pembrolizumab) in patients with metastatic small cell neuroendocrine prostate cancer.

Source link
#FDA #Grants #Fast #Track #Designation #BioXcel #Therapeutics039 #Prostate #Cancer #Therapy